Progressive Multifocal Leukoencephalopathy Clinical Trial
Official title:
An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate). Researchers will also look to estimate the incidence of other serious opportunistic infections among patients who switch to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate)
This is an observational cohort study utilising all available data from the Tysabri TOUCH (TYSABRI Outreach: Unified Commitment to Health) prescribing programme (US) supplemented with data from European Union (EU) multiple sclerosis (MS) registries to estimate the risk of PML and other serious opportunistic infections (OIs) among patients on Tysabri who have switched from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate). This study will provide cumulative data from its two components: a retrospective component (data captured prior to 01 January 2016) and a prospective component (data captured, and patients followed up, from 01 January 2016 through 31 December 2023; total prospective study duration of 8 years). All patients who switched to Tysabri from another DMT through 31 December 2020 will be included. The study will continue to follow-up patients until 31 December 2023 to allow for a minimal follow-up of 3 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02004444 -
JC Virus Reactivation in Multiple Sclerosis
|
N/A | |
| Terminated |
NCT01211639 -
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
|
N/A | |
| Recruiting |
NCT05849467 -
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
|
Phase 1 | |
| Recruiting |
NCT01730131 -
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
|
||
| Recruiting |
NCT04781309 -
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
|
Early Phase 1 | |
| Completed |
NCT02694783 -
Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells
|
Early Phase 1 | |
| Completed |
NCT01132053 -
Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
|
||
| Terminated |
NCT00746941 -
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
|
Phase 1/Phase 2 | |
| Completed |
NCT02895581 -
Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy
|
N/A | |
| Recruiting |
NCT04453917 -
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
|
N/A | |
| Not yet recruiting |
NCT05541549 -
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
|
Phase 2 | |
| Recruiting |
NCT04091932 -
Treatment of PD-1 Inhibitor in AIDS-associated PML
|
Phase 2 | |
| Not yet recruiting |
NCT06276504 -
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
|
Phase 2/Phase 3 |